Immunodeficiency 35 (IMD35) Cell Models for Research

Immunodeficiency 35 (IMD35) is a rare primary immunodeficiency disorder caused by mutations in the CD40LG gene, located on the X chromosome. The exact prevalence is unknown, but it is estimated to affect 1 in 1,000,000 males worldwide. The condition is characterized by recurrent bacterial and opportunistic infections, leading to significant morbidity and mortality if untreated. According to the National Cancer Institute (NCI), patients with IMD35 have an increased risk of developing certain cancers, particularly lymphomas, due to impaired immune surveillance. The 5-year survival rate for patients with severe combined immunodeficiency (SCID) phenotypes, which includes IMD35, is approximately 70% with early hematopoietic stem cell transplantation (HSCT). Without treatment, the condition is often fatal in the first two decades of life.

IMD35 serves as an excellent model for studying T-cell and B-cell interactions, particularly the CD40-CD40L signaling pathway. This pathway is crucial for immunoglobulin class switching, germinal center formation, and memory B-cell development. Research on IMD35 has provided insights into the molecular mechanisms of humoral immunity and has implications for vaccine development and immunotherapy. Public datasets, such as those from the NCBI Gene and ClinVar, provide comprehensive information on CD40LG mutations and their clinical phenotypes. Open questions include the role of specific CD40LG mutations in disease severity and the potential for gene therapy approaches.

IMD35 is primarily an immunodeficiency disorder, but its molecular pathogenesis involves the disruption of the CD40-CD40L signaling pathway. The key steps are:

1. CD40LG gene encodes CD40 ligand (CD40L), a type II transmembrane protein expressed on activated T cells.

2. CD40L binds to CD40 receptor on B cells, dendritic cells, and macrophages.

3. This interaction triggers downstream signaling cascades, including NF-κB, MAPK, and PI3K/AKT pathways.

4. These pathways are essential for B-cell activation, proliferation, and immunoglobulin class switching.

5. Mutations in CD40LG lead to loss of functional CD40L, resulting in defective T-cell-dependent B-cell responses.

This defect leads to the characteristic phenotype of hyper-IgM syndrome type 1, with low IgG, IgA, and IgE levels but normal or elevated IgM.

Data from TCGA and COSMIC indicate that CD40LG mutations are the sole genetic cause of IMD35. The majority of mutations are private, with no single hotspot. ClinVar lists over 300 pathogenic variants in CD40LG associated with IMD35.

The loss of CD40L function disrupts multiple signaling networks:

• • NF-κB pathway: CD40L binding to CD40 activates NF-κB, which is critical for B-cell survival and proliferation. In IMD35, this pathway is impaired, leading to reduced B-cell function.
• • MAPK pathway: CD40 engagement also activates ERK, JNK, and p38 MAPKs, which regulate cytokine production and class switching. Defective signaling results in impaired immune responses.
• • PI3K/AKT pathway: This pathway is involved in B-cell survival and metabolism. Its dysregulation contributes to the immunodeficiency phenotype.

Additionally, the lack of CD40L affects T-cell-dependent activation of dendritic cells, leading to impaired antigen presentation and T-cell priming.

Organoids derived from patient-derived induced pluripotent stem cells (iPSCs) can recapitulate the immune microenvironment and are useful for studying the effects of CD40LG mutations in a 3D context.

• • CD40LG knockout mice: These mice exhibit a phenotype similar to human IMD35, with reduced serum IgG, IgA, and IgE levels and impaired germinal center formation.
• • CD40LG mutant mice: Point mutations in the CD40LG gene have been generated to study specific pathogenic variants.
• • Patient-derived xenograft (PDX) models: Immunodeficient mice engrafted with patient immune cells can be used to study the functional consequences of CD40LG mutations.
• • Genetically engineered mouse models (GEMMs): CRISPR-Cas9 has been used to introduce specific CD40LG mutations into mouse embryonic stem cells to create models of IMD35.

CRISPR-Cas9 gene editing allows the creation of isogenic cell lines with specific CD40LG mutations. For example:

• • CD40LG knockout cell lines: Generated by introducing a frameshift mutation in exon 1 of CD40LG, resulting in loss of protein expression. These are useful for studying the loss-of-function phenotype.
• • CD40LG point mutation knock-in lines: Specific pathogenic mutations (e.g., p.Gly116Arg) can be introduced to model the disease in a physiologically relevant context.

These gene-edited cell models are commercially available from various sources and are sequence-verified to ensure accuracy. They provide a valuable tool for drug discovery, functional genomics, and target validation.

Gene-edited cell lines are used to validate the function of CD40LG and other genes in the CD40 signaling pathway. For example, CD40LG knockout Jurkat cells can be used to study the effects of CD40L loss on T-cell activation and cytokine production. Knock-in lines with specific mutations can be used to assess the impact of those mutations on protein function and downstream signaling.

Isogenic pairs (wild-type vs. CD40LG knockout) are used in high-throughput screening to identify compounds that can restore CD40L function or bypass the defective pathway. These models are also useful for testing the efficacy of gene therapy approaches, such as lentiviral delivery of functional CD40LG. Additionally, they can be used to study resistance mechanisms to immunomodulatory drugs.

CRISPR-based synthetic lethality screens using CD40LG knockout cells can identify genes that are essential for cell survival in the absence of CD40L. These genes may serve as potential therapeutic targets for treating IMD35. Furthermore, gene-edited cells can be used to discover biomarkers that predict patient response to HSCT or gene therapy.